Sign up for News by Email
All Releases
View Summary Threshold Pharmaceuticals Announces Results of Two New Preclinical Studies Evaluating Novel Combinations of TH-302 With Immunotherapy, Antiangiogenic Therapy, and Radiotherapy to Be Presented at AACR Annual Meeting 2014
Apr 3, 2014
PDF 12.7 KB
View Summary Threshold Pharmaceuticals' Partner Merck KGaA, Darmstadt, Germany Initiates Phase 1 Dose Escalation Study of TH-302 in Combination With Gemcitabine and Nab-paclitaxel (Abraxane(R)) in Pancreatic Cancer
Mar 27, 2014
PDF 14.0 KB
View Summary Threshold Pharmaceuticals Reports Fourth Quarter and Year End 2013 Financial and Operational Results
Mar 6, 2014
PDF 24.1 KB
View Summary Threshold Pharmaceuticals Announces Presentations and Webcasts at Three Upcoming Investor Conferences
Feb 20, 2014
PDF 9.7 KB
View Summary Threshold Pharmaceuticals Announces Target Enrollment of 620 Patients Achieved in Pivotal Phase 3 Trial of TH-302 in Advanced Soft Tissue Sarcoma
Dec 30, 2013
PDF 12.7 KB
View Summary Threshold Pharmaceuticals Reports TH-302 Data at the 55th Annual Meeting of the American Society of Hematology (ASH)
Dec 7, 2013
PDF 16.8 KB
View Summary Threshold Pharmaceuticals Announces Presentation and Webcast at the Oppenheimer 24th Annual Healthcare Conference
Dec 3, 2013
PDF 9.2 KB
View Summary Threshold Pharmaceuticals Announces New Clinical Data on TH-302 and Avastin(R) (Bevacizumab) in Recurrent Glioblastoma Following Bevacizumab Failure
Nov 22, 2013
PDF 14.3 KB
View Summary Threshold Pharmaceuticals Announces New Data on the Combination of TH-302 and Avastin(R) (bevacizumab) in Recurrent Glioblastoma to Be Presented at WFNO/SNO
Nov 11, 2013
PDF 11.7 KB
View Summary Threshold Pharmaceuticals Announces TH-302 Data to Be Presented at ASH
Nov 7, 2013
PDF 11.6 KB
View Summary Threshold Pharmaceuticals Reports Third Quarter 2013 Financial and Operational Results
Nov 4, 2013
PDF 22.2 KB
View Summary Threshold Pharmaceuticals Announces Early Clinical Data for Combining TH-302 With Antiangiogenic Agents in Advanced Solid Tumors
Oct 21, 2013
PDF 57.4 KB
View Summary Threshold Pharmaceuticals Announces New Data on TH-302 to Be Presented at AACR-NCI-EORTC
Oct 7, 2013
PDF 12.4 KB
View Summary Threshold Pharmaceuticals Announces Presentation and Webcast at the Stifel Healthcare Conference 2013
Sep 5, 2013
PDF 9.2 KB
View Summary Threshold Pharmaceuticals Initiates Phase 2 Study of TH-302 in Patients With Advanced Melanoma
Aug 8, 2013
PDF 13.1 KB
View Summary Threshold Pharmaceuticals Reports Second Quarter 2013 Financial and Operational Results
Aug 1, 2013
PDF 21.4 KB
View Summary Threshold Pharmaceuticals Announces Presentation and Webcast at the JMP Securities Healthcare Conference
Jul 2, 2013
PDF 9.2 KB
View Summary Threshold Pharmaceuticals Announces Update on Its Phase 3 Trial in Soft Tissue Sarcoma
Jul 1, 2013
PDF 17.2 KB
View Summary Threshold Pharmaceuticals Announces Data From Two Ongoing Phase 1/2 Trials of TH-302 at the 2013 ASCO Annual Meeting
Jun 2, 2013
PDF 14.4 KB
View Summary Threshold Pharmaceuticals Announces Presentations and Webcasts at Three Upcoming Investor Conferences
May 9, 2013
PDF 9.5 KB
Showing 1-20 of 234 Page: 1 2 3 4 5 ... 12  Next 20
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue